Pharmaceutical lifecycle management
16 June 2017 by
IHS Markit and Context Matters have for the first time combined these two diverse datasets under one platform so that companies...
8 November 2016 by Gustav Ando
Proposition 61 on today's California ballot
14 September 2016 by Sophie Cairns
Japan’s Ministry of Foreign Affairs issued an unusually direct warning of “great turmoil” in a post-Brexit scenario
9 September 2016 by Eóin Ryan
Ireland’s IRP framework underwent a major shake-up in August including an expansion of the basket
19 July 2016 by Milena Izmirlieva
Pinpointing the exact impact of Brexit on healthcare spending and pharmaceutical spending remains a moving target
6 July 2016 by Cecilia Chui
Immunotherapy and precision medicine centre-stage at ASCO
17 June 2016 by Anne-Charlotte Ackermann
A close look at France's formal BIA and access to HCV meds
28 December 2015 by Jing Zhang
Understanding the twentieth-largest pharmaceutical market in the world
10 December 2015 by Milena Izmirlieva
A look at the pricing for PCSK9 inhibitors for cholesterol
25 August 2015 by Cameron Lockwood
A close look at the market-specific differences in terms of how payers would like to see manufacturers address the REA gap
30 June 2015 by Milena Izmirlieva
Are there signs of actual changes in the United States P&R environment as a result of the 'Sovaldi Effect'?
3 March 2015 by Milena Izmirlieva
Learn more about the trends in risk sharing agreements (known as patient access schemes (PAS) in some markets) and the...
3 December 2014 by Milena Izmirlieva
For pharma manufacturers early access to innovation should generally translate into early patient access and earlier revenues than...
About the Life Sciences BlogIndustry insights from the IHS Markit Life Sciences team covering market access, pricing and reimbursement, emerging markets, generics strategies, therapeutic development pathways, forecasting and market sizing, and general competitive intelligence. IHS Markit Blog Home »
Tweets by @IHS4LifeScience